Plasticizer Exposure and Its Consequences on Health

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMedical University of Vienna

About this trial

Plasticizers are chemicals commonly found in many everyday items, from food packaging to medical equipment. Although they are pervasive in our daily lives, researchers still don't have a clear picture of their long-term effects on human health. Evidence suggests that these substances might disrupt various biological functions such as the immune system, the balance of gut bacteria, hormone regulation, and brain processes. While some studies have linked plasticizer exposure to health issues, definitive data from human studies are still lacking.

The PEACH study aims to bridge these knowledge gaps by investigating how plasticizers affect human health. The study focuses on understanding how these chemicals are absorbed, distributed, and accumulated in the body across different groups of patients. The investigators are particularly interested in how plasticizers influence gut microbiota and the functionality of immune cells, as well as their effects on neurotransmitters involved in brain function.

A combination of patient data, systems biology, and laboratory models will be used to thoroughly assess the biological impacts of plasticizers. Advanced techniques such as mass spectrometry will aid in studying toxicokinetic properties, sequencing technologies will be used to examine immune effects, and radiouptake assays will be employed to explore interactions with neurotransmitter transport. This comprehensive methodology will provide new insights into the effects of both short-term and long-term exposure to plasticizers.

The PEACH study introduces innovative methods to the field, aiming to create a robust model for understanding how plasticizer compounds behave in the human body. It employs state-of-the-art techniques to assess the dynamics of these chemicals, marking a significant advancement in environmental health research.

Eligibility criteria

Qualifiers

Inclusion: Adult, homozygous ß-Thalassemia Major, transfusion dependency.

Exclusion: Plastic implants, chronic infectious disease, pregnancy.

Inclusion: Adult, homozygous/heterozygous ß-Thalassemia Intermedia/Minor

Exclusion: Plastic implants, chronic infectious disease, pregnancy, transfusion dependency

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

120 Participants
are grouped into 6 trial groups

6

Trial groups

See each trial group below.

Sponsors and collaborators

Medical University of Vienna

Lead sponsor

University of Vienna

Collaborator